Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The White House is taking right approach in fighting the Covid-19 delta variant, Gottlieb says

The Biden administration is taking the right approach in fighting the highly contagious Covid-19 delta variant by deploying response teams to vulnerable communities, Dr. Scott Gottlieb said Thursday.

“I think that the administration is doing the right thing, in terms of shifting their strategy,” Gottlieb, the former FDA chief under former President Donald Trump, told CNBC’s “The News with Shepard Smith” about the new administration’s grassroots approach.

Gottlieb explained that the targeted response can help teams focus on vaccinating those communities vulnerable to Covid and the delta variant.

“Right now, we need to shift to a grassroots strategy and try to put resources into local communities to allow local groups to encourage people to get vaccinated, put the vaccines into the hands of doctors, and find ways to get more vaccines into the hands of small providers who can encourage their patients to get vaccinated,” Gottlieb said.

The delta variant is driving a sharp increase in new Covid cases across the nation, and currently makes up about 25% of sequenced new cases in the U.S. Officials say they expect it to become the dominant strain in the country, eclipsing the currently dominant alpha variant.

Centers for Disease Control and Prevention Director Rochelle Walensky attributed the spike, in part, to lagging vaccination rates. The CDC director added that about one-third of all counties across the nation have so far vaccinated less than 30% of their population. She said the majority of them are in the South and Midwest.

Source: CNBC

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!